— STEP-HFpEF trial results come out consistent across ejection fractionCLEVELAND — Semaglutide 2.4 mg (Wegovy) improved outcomes across the range of moderately reduced and preserved ejection fraction in heart failure (HFmrEF, HFpEF) related to obesity, a prespecified secondary analysis of the STEP-HFpEF trial showed.The benefits were consistent across subgroups, reported Javed Butler, MD, MPH, MBA, […]
